Reviewing SELLAS Life Sciences Group (NASDAQ:SLS) & Pharming Group (OTCMKTS:PHGUF)
by Doug Wharley · The Cerbat GemSELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) and Pharming Group (OTCMKTS:PHGUF – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
Institutional & Insider Ownership
17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares SELLAS Life Sciences Group and Pharming Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SELLAS Life Sciences Group | N/A | N/A | -$26.86 million | ($0.23) | -35.00 |
| Pharming Group | $376.13 million | 2.05 | $2.85 million | $0.02 | 57.50 |
Pharming Group has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
SELLAS Life Sciences Group has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for SELLAS Life Sciences Group and Pharming Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SELLAS Life Sciences Group | 1 | 0 | 1 | 0 | 2.00 |
| Pharming Group | 0 | 0 | 0 | 0 | 0.00 |
SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential upside of 24.22%. Given SELLAS Life Sciences Group’s stronger consensus rating and higher possible upside, equities research analysts clearly believe SELLAS Life Sciences Group is more favorable than Pharming Group.
Profitability
This table compares SELLAS Life Sciences Group and Pharming Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SELLAS Life Sciences Group | N/A | -47.12% | -42.63% |
| Pharming Group | 3.30% | 4.64% | 2.55% |
Summary
Pharming Group beats SELLAS Life Sciences Group on 7 of the 13 factors compared between the two stocks.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.